CD8A and neoplasm: Tumor growth was monitored twice a week and the raising of NPMc-specific CD8+ T cells was evaluated through in vivo cytotoxicity assay (Arranz et al., 2014) by injecting mice with splenocytes pulsed 1 hr with NPMc-derived MHC-I peptides or with an unrelated peptide.